Fusion of cell-penetrating peptides to thermally responsive biopolymer improves tumor accumulation of p21 peptide in a mouse model of pancreatic cancer

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1649-1658

  Walker, Leslie R ^a   Ryu, Jung Su ^a   Perkins, Eddie ^b   McNally, Lacey R ^c   Raucher, Drazen ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Elastin like polypeptide; Macromolecule; Peptide; Targeted drug delivery

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ELASTIN LIKE POLYPEPTIDE P21 FUSION PEPTIDE; P21 ELASTIN LIKE POLYPEPTIDE BAC FUSION PEPTIDE; UNCLASSIFIED DRUG; BIOPOLYMER; CELL PENETRATING PEPTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; FEMALE; HEATING; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREATIC CANCER CELL LINE; TRANSITION TEMPERATURE; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TEMPERATURE; TUMOR CELL CULTURE;

ANIMALS; BIOPOLYMERS; CELL PROLIFERATION; CELL-PENETRATING PEPTIDES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE; TUMOR CELLS, CULTURED;

EID: 84908060919     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S60451     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts and Figures 2014. Atlanta: American Cancer Society; 2014. Available from: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed January 6, 2014.
2. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21(5):797-802.
3. Raucher D, Chilkoti A. Enhanced uptake of a thermally responsive polypeptide by tumor cells in response to its hyperthermia-mediated phase transition. Cancer Res. 2001;61(19):7163-7170.
4. Bidwell GL 3rd, Perkins E, Hughes J, Khan M, James JR, Raucher D. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS One. 2013;8(1):e55104.
5. Bidwell GL 3rd, Perkins E, Raucher D. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett. 2012;319(2):136-143.
6. Chilkoti A, Dreher MR, Meyer DE, Raucher D. Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev. 2002;54(5): 613-630.
7. Moktan S, Perkins E, Kratz F, Raucher D. Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo. Mol Cancer Ther. 2012;11(7):1547-1556.
8. Walker L, Perkins E, Kratz F, Raucher D. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm. 2012;436(1-2):825-832.
9. Bidwell GL 3rd, Raucher D. Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv Drug Deliv Rev. 2010;62(15): 1486-1496.
10. Massodi I, Bidwell GL 3rd, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release. 2005;108(2-3):396-408.
11. Mutoh M, Lung FD, Long YQ, Roller PP, Sikorski RS, O'Connor PM. A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 1999;59(14):3480-3488.
12. Bidwell GL 3rd, Davis AN, Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release. 2009;135(1):2-10.
13. Massodi I, Moktan S, Rawat A, Bidwell GL 3rd, Raucher D. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int J Cancer. 2010;126(2):533-544.
14. Meyer DE, Chilkoti A. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol. 1999;17(11): 1112-1115.
15. McPherson DT, Xu J, Urry DW. Product purification by reversible phase transition following Escherichia coli expression of genes encoding up to 251 repeats of the elastomeric pentapeptide GVGVP. Protein Expr Purif. 1996;7(1):51-57.
16. Daniell H, Guda C, McPherson DT, Zhang X, Xu J, Urry DW. Hyperexpression of a synthetic protein-based polymer gene. Methods Mol Biol. 1997;63:359-371.
17. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Chilkoti A. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res. 2007;67(9):4418-4424.
18. Mikecin AM, Walker LR, Kuna M, Raucher D. Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines. Anticancer Drugs. 2014;25(2):189-199.
19. Liu W, Dreher MR, Furgeson DY, et al. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release. 2006;116(2):170-178.
20. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006;98(5):335-344.
21. Raucher D, Moktan S, Massodi I, Bidwell GL 3rd. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv. 2009;6(10):1049-1064.
22. Bidwell GL 3rd, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther. 2005;4(7):1076-1085.
23. Massodi I, Bidwell GL 3rd, Davis A, et al. Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin Exp Metastasis. 2009;26(3):251-260.
24. Bidwell GL 3rd, Whittom AA, Thomas E, Lyons D, Hebert MD, Raucher D. A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides. 2010;31(5): 834-841.
25. Moktan S, Raucher D. Anticancer activity of proapoptotic peptides is highly improved by thermal targeting using elastin-like polypeptides. Int J Pept Res Ther. 2012;18(3):227-237.
26. Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry. 2002;41(48):14150-14157.
27. Liu W, Dreher MR, Chow DC, Zalutsky MR, Chilkoti A. Tracking the in vivo fate of recombinant polypeptides by isotopic labeling. J Control Release. 2006;114(2):184-192.
28. Moktan S, Ryppa C, Kratz F, Raucher D. A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis. Invest New Drugs. 2012;30(1):236-248.
29. Bidwell GL 3rd, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol. 2006;71(3):248-256.